ZOLL® Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it will display its portfolio of clinical resuscitation products including the LifeVest® Wearable Defibrillator, along with sudden cardiac death (SCD) education and screening tools, in Booth #947 at Heart Rhythm 2015, the Heart Rhythm Society’s 36th Annual Scientific Sessions, May 13-16 at the Boston Convention and Exhibition Center.
The LifeVest will be discussed during the following scientific sessions:
• Pasquale Santangeli, MD, University of Pennsylvania, will present “Usage of a Wearable Cardioverter Defibrillator in Patients with Advanced Heart Failure,” Friday, May 15, 3:15-4:15 pm., EPicenter, Exhibit Hall, Poster #PO0542.
• Chingping Wan, MD, ZOLL, will present “One-year Outcome for Medicare Beneficiaries with AMI Using a WCD,” Friday, May 15, 3:15-4:15 pm., EPicenter, Exhibit Hall, Poster #PO0558.
The LifeVest protects patients at risk for SCD. It is used for a wide range of patient conditions or situations, including following a myocardial infarction, before or after coronary revascularization, and for those with cardiomyopathy or congestive heart failure that places them at particular risk. The LifeVest gives physicians time to optimize medical therapy and assess a patient’s long-term risk for sudden death.
In the WEARIT-II prospective registry of 2,000 patients prescribed the LifeVest, the sustained VT/VF event rate was high with 22 events per 100 patient-years 2.1% of patients had a VT/VF event.1 One in 14 patients experienced a clinically meaningful arrhythmia requiring intervention while wearing the LifeVest.1 The LifeVest Network Online Patient Data Management System provides customizable tools for physicians and clinicians to access these captured arrhythmias, like atrial fibrillation or non-sustained ventricular tachyarrhythmias, and determine the appropriate intervention.
The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCD. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.
The LifeVest is covered by most health plans in the United States, including commercial, state, and federal plans.
Additional products on display from ZOLL include:
• The AutoPulse® Resuscitation System provides consistent, high-quality CPR to victims of sudden cardiac arrest. Easy to use and battery operated, its load-distributing LifeBand® squeezes the patient’s entire chest to improve blood flow to the heart and brain. The only device of its kind, AutoPulse automatically sizes to the patient, and has shown improved survival in numerous clinical trials.2,3
• The R Series® Monitor/Defibrillator is designed to promote consistent, high-quality CPR and high-current defibrillation for adults and pediatrics. Its featured technologies include Real CPR Help® to provide real-time feedback on compression quality, See-Thru CPR® to reduce pause time by filtering the CPR artifact, and EtCO2 to signal the earliest changes in patient condition. ZOLL offers customers more than just a way to deliver a shock. Tools to help improve CPR quality are included, which improves outcomes.4
About ZOLL Medical Corporation
ZOLL Medical Corporation (zoll.com), an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, therapeutic temperature management, and ventilation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care.
About Asahi Kasei
The Asahi Kasei Group (asahi-kasei.co.jp) is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 29,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries.
1. Kutyifa V, et al. Results from the Prospective Registry of Patients Using the Wearable Defibrillator (WEARIT-II Registry), presented as Late Breaking Clinical Trial at the European Society of Cardiology Congress, September 3, 2014.
2. Wesfall M, et al. Mechanical Vs. Manual Chest Compressions in Out-of-Hospital Cardiac Arrest: A Meta-Analysis. Crit Care Med. 2013 Jul;41(7):1782‐9.
3. Wik L, et al. Manual vs. Integrated Automatic Load-distributing Band CPR with Equal Survival after Out- of- Hospital Cardiac Arrest. The Randomized CIRC Trial. Resuscitation 85 (2014) 741 748.
4. Bobrow BJ, et al. The Influence of Scenario-based Training and Real-time Audiovisual Feedback on Pre-hospital Cardiopulmonary Resuscitation Quality and Survival from Out-of-hospital Cardiac Arrest. Ann Emerg Med. 2013 Jul;62(1):47 56.e1. Epub 2013 Mar 7.
Copyright © 2015 ZOLL Medical Corporation. AutoPulse, LifeBand, LifeVest, Real CPR Help, R Series, See-Thru CPR, and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All product names are the property of their respective owners.